The Role of Acupoint Application of Herbal Medicine for Asthma: Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials

Table 1

Characteristics of included studies.

First author, year [ref.]	Country	Age (years, mean ± SD)	Sample size (R/A)	Asthma history Mean ± SD (years)
Yang, 2018 [15]	China	T: 56.67 ± 10.62	T: 30/30	T: 10.17 ± 6.79
		C: 56.80 ± 12.32	C: 30/30	C: 9.87 ± 5.29
Wang, 2017 [16]	China	T: 8.0 ± 2.8	T: 60/60	T: 1.68 ± 0.88
		C: 7.5 ± 2.6	C: 60/60	C: 1.67 ± 0.67
Wang (b), 2017 [17]	China	T:7.6 ± 2.8	T: 50/50	T: 1.58 ± 0.78
		C:7.5 ± 2.6	C: 50/50	C: 1.57 ± 0.72
Ma, 2016 [18]	China	T: 7.6 ± 2.5	T: 54/54	T:2.9 ± 1.4
		C: 8.1 ± 2.7	C: 53/53	C:3.2 ± 1.5
Wang, 2016 [19]	China	T: 48 ± 6.4	T: 44/44	T: 9.5 ± 3.5
		C: 47 ± 6.9	C: 44/44	C: 7.3 ± 3.1
Shi, 2014 [20]	China	T: 4.8 ± 0.3	T: 46/46	T:7.50 ± 3.30
		C: 4.9 ± 0.5	C: 46/46	C:7.30 ± 3.10
Chang, 2014 [21]	China	T: 37.21 ± 12.90	T: 75/75	T:18.28 ± 8.90 M
		C: 38.91 ± 11.85	C: 68/68	C:19.91 ± 9.18 M
Liu, 2018 [22]	China	T: 50 ± 15	T: 30/30	T:8.7 ± 4.7
		C: 49 ± 12	C: 30/30	C:9.1 ± 4.7
Tian, 2020 [23]	China	T: 54.82 ± 11.77	T: 56/56	T: 2–7
		C: 53.6 ± 13.28	C: 55/55	C: 3–7
Shang, 2013 [24]	China	T:35.0 ± 11.0	T: 80/80	T: NR
		C:32.0 ± 12.0	C: 40/40	C: NR
Lu, 2011 [25]	China	T: 46.82 ± 10.11	T: 35/35	T:4.76 ± 1.23
		C: 47.42 ± 11.84	C: 35/35	C:5.42 ± 1.74
Bai, 2010 [26]	China	T: 19–52	T: 42/42	T: 0.25–6
		C: 25–51	C: 42/42	C: 0.16–5
Yao, 2009 [27]	China	T: 45.3 ± 12.0	T: 125/125	T: 12.4 ± 3.4
		C: 45.4 ± 12.7	C: 63/63	C: 11.8 ± 4.7
Yu, 2009 [28]	China	NR	T: 33/33	NR
			C: 17/17
Yao, 2007 [29]	China	T: 46.2 ± 12.1	T: 44/44	NR
		C: 51.0 ± 11.8	C: 22/22
Mi, 2005 [30]	China	T: 18–65	T: 181/181	T: 0.16–20
		C: 18–65	C: 181/181	C: 0.08–30

Abbreviations: T: treatment, C: control, R: number of subjects randomized, A: number of subjects analyzed, M: month, NR: not reported, and SD: standard deviation.